Hsa‑circRNA‑G004213 promotes cisplatin sensitivity by regulating miR‑513b‑5p/PRPF39 in liver cancer

Abstract

In recent years, increasing evidence has confirmed that exosomal circular RNAs (circRNAs) serve a crucial role in the prognostic prediction and diagnosis of liver cancer (LC). The present study compared the expression patterns of exosomal circRNAs during transarterial chemoembolization (TACE). CircRNA sequencing analysis identified 390 differentially expressed circRNAs between the prior TACE and following the first TACE operation groups and 489 differentially expressed circRNAs between the prior to TACE and following the second TACE operation groups. Gene Ontology analysis of the differentially expressed circRNAs demonstrated that they were associated with fatty acid metabolism, receptor binding and membrane protein complexes. Kyoto Encyclopedia of Genes and Genomes pathway analysis predicted that protein digestion and absorption pathways were activated following TACE. A novel gene was screened out; hsa-circRNA-G004213 (circ-G004213) was significantly upregulated following TACE (fold change >10, P<0.01). Further analysis found circ-G004213 significantly increased the cisplatin sensitivity of HepG2 cells and positively associated with the prognosis of tumor-bearing mice. Based on the potential downstream miRNAs and mRNAs, the circRNA-miRNA-mRNA network was constructed. It was demonstrated that circ-G004213 regulated cisplatin resistance via the miR-513b-5p/PRPF39 axis. Finally, the present study confirmed that circ-G004213 was positively associated with the prognosis of patients with LC following TACE. Therefore, circ-G004213 may be used as an indicator for predicting the efficacy of TACE.

N6-Methyladenosine-regulated LINC00675 suppress the proliferation, migration and invasion of breast cancer cells via inhibiting miR-513b-5p

“…Previous studies have already identified the targets of miR-513b-5p, such as DUSP11, LARP4, IRF2, E2F5, PRPF39 and PTEN [ 23–27 ]. Whether LINC00675 affected the expression of the targets of miR-513b-5p was then assessed.…”

“…miR-513b-5p exerts oncogenic or suppressive function in different cancers [ 23–27 ], but its effect on BC cells remains unknown. To elucidate whether LINC00675 functions via miR-513b-5p, rescue experiments were carried out.…”

“…Previous studies have reported that miR-513b-5p is involved in the proliferation, metastasis and drug resistance of cancer cells. The targets of miR-513b-5p includes DUSP11, LARP4, IRF2, E2F5, PRPF39, and PTEN [ 23–27 ]. Here, our date demonstrated that LINC00675 significantly upregulated the expression of LARP4, IRF2, PRPF39 and PTEN, but could not influence the expression of DUSP11 and E2F5.…”

“…Loss of IRF2 leads to immune evasion through decreased MHC class I antigen presentation and increased PD-L1 expression in cancers [ 33 ]. PRPF39 is a regulator of cisplatin sensitivity in liver cancer [ 23 ]. PTEN is a well-known tumor suppressor.…”

Circ_PIP5K1A regulates cisplatin resistance and malignant progression in non-small cell lung cancer cells and xenograft murine model via depending on miR-493-5p/ROCK1 axis

“…CircRNAs have pivotal roles in various kinds of biological processes, including carcinogenesis, cancer progression and drug resistance [ 20 ]. Qian et al discovered that circ-G004213 significantly elevated the DDP sensitivity in liver cancer via regulating the miR-513b-5p/pre-mRNA processing factor 39 (PRPF39) levels [ 21 ]. Wei et al reported that circSAMD4A increased doxorubicin resistance in osteosarcoma cells through the effect on miR-218-5p/krüppel-like factor 8 (KLF8) axis [ 22 ].…”